神州细胞抗PD-1单抗联合疗法获批，百利天恒GNC-038 四抗注射液杀入自免领域，强生古塞奇尤单抗在华获批克罗恩病适应症

医药经济报2025-03-01

神州细胞抗PD-1单抗联合疗法获批，一线治疗肝癌2月28日，中国国家药监局（NMPA）官网公示，神州细胞控股子公司神州细胞工程递交的菲诺利单抗注射液（SCT-I10A）与贝伐珠单抗注射液（SCT510）联合疗法的上市许可申请已获得批准。根据神州细胞此前发布的新闻稿，该药本次获批的适应症为：适用于既往未接受过系统治疗的不可切除或转移性肝细胞癌患者。截图来源：NMPA官网据世界卫生组织国际癌症研究机构...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2516580463?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-03-01 11:48","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2516580463","market":"us","top_or_hot":-1,"title":"神州细胞抗PD-1单抗联合疗法获批，百利天恒GNC-038 四抗注射液杀入自免领域，强生古塞奇尤单抗在华获批克罗恩病适应症","media":"医药经济报","content":"<div>\n<p>神州细胞抗PD-1单抗联合疗法获批，一线治疗肝癌2月28日，中国国家药监局（NMPA）官网公示，神州细胞控股子公司神州细胞工程递交的菲诺利单抗注射液（SCT-I10A）与贝伐珠单抗注射液（SCT510）联合疗法的上市许可申请已获得批准。根据神州细胞此前发布的新闻稿，该药本次获批的适应症为：适用于既往未接受过系统治疗的不可切除或转移性肝细胞癌患者。截图来源：NMPA官网据世界卫生组织国际癌症研究机构...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301115219abe18cd0&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>神州细胞抗PD-1单抗联合疗法获批，百利天恒GNC-038 四抗注射液杀入自免领域，强生古塞奇尤单抗在华获批克罗恩病适应症</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n神州细胞抗PD-1单抗联合疗法获批，百利天恒GNC-038 四抗注射液杀入自免领域，强生古塞奇尤单抗在华获批克罗恩病适应症\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-03-01 11:48 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301115219abe18cd0&s=b><strong>医药经济报</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>神州细胞抗PD-1单抗联合疗法获批，一线治疗肝癌2月28日，中国国家药监局（NMPA）官网公示，神州细胞控股子公司神州细胞工程递交的菲诺利单抗注射液（SCT-I10A）与贝伐珠单抗注射液（SCT510）联合疗法的上市许可申请已获得批准。根据神州细胞此前发布的新闻稿，该药本次获批的适应症为：适用于既往未接受过系统治疗的不可切除或转移性肝细胞癌患者。截图来源：NMPA官网据世界卫生组织国际癌症研究机构...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301115219abe18cd0&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1914381329.SGD","symbol_name":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301115219abe18cd0&s=b","article_id":"2516580463","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250301115219abe18cd0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2516580463","pubTimestamp":1740800927,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"神州细胞抗PD-1单抗联合疗法获批，一线治疗肝癌2月28日，中国国家药监局官网公示，神州细胞控股子公司神州细胞工程递交的菲诺利单抗注射液与贝伐珠单抗注射液联合疗法的上市许可申请已获得批准。菲诺利单抗为神州细胞自主研发的重组人源化抗PD-1 IgG4型单克隆抗体注射液，首个适应症头颈部鳞状细胞癌已经于2025年2月获NMPA批准上市。这一消息标志着古塞奇尤单抗在克罗恩病适应症上的全球首个批准，为国内克罗恩病患者带来了新的希望。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"688506":"百利天恒","688520":"神州细胞","LU1914381329.SGD":"Allianz Best Styles Global Equity Cl ET Acc H2-SGD","LU2505996509.AUD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (AUDHDG) INC","SG9999002232.USD":"Allianz Global High Payout USD","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","IE00BGHQF631.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) ACC","LU1244550221.USD":"FRANKLIN GLOBAL MULTI-ASSET  INCOME \"A\" (USDHEDGED) INC (M)","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","BK4550":"红杉资本持仓","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE00BDGV0183.EUR":"GUINNESS GLOBAL EQUITY INCOME \"C\" (EUR) INC","IE0034235303.USD":"PINEBRIDGE US RESEARCH ENHANCED CORE EQUITY \"A\" (USD) ACC","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00B42XCP33.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) INC","LU1059921491.USD":"NORDEA 1 GLOBAL STABLE EQUITY \"HB\" (USDHDG) ACC","BK4007":"制药","LU1162221912.USD":"FRANKLIN INCOME \"A\" (USD) ACC","LU2129689605.HKD":"FRANKLIN GLOBAL INCOME \"A\" (HKD) INC","BK4559":"巴菲特持仓","BK4023":"应用软件","PD":"PagerDuty, Inc.","JNJ":"强生","LU1032466523.USD":"高盛全球多资产收益组合Acc","LU2129689514.USD":"FRANKLIN GLOBAL INCOME \"A\" (USD) INC","LU1929549753.HKD":"FRANKLIN INCOME \"A\" (HKD) INC","LU1221951046.USD":"NORDEA 1 STABLE RETURN \"HM\" (USDHDG) INC","LU2592432038.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"A\" (USD) ACC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU1032955483.USD":"NORDEA 1 STABLE RETURN \"HB\" (USDHDG) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","IE00BVYPNW00.USD":"GUINNESS GLOBAL EQUITY INCOME \"C\" (USD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","BK4533":"AQR资本管理(全球第二大对冲基金)","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1732800096.USD":"摩根大通环球收益基金A (irc)","LU2430703251.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4\" (USD) INC","LU0795875169.SGD":"JPMorgan Investment Funds - Global Income A (div) SGD-H","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU1732799900.SGD":"JPMorgan Investment Funds - Global Income A (irc) SGD-H","LU2505996681.GBP":"WELLINGTON MULTI-ASSET HIGH INCOME \"AM4H\" (GBPHDG) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","BK4592":"伊斯兰概念","BK4504":"桥水持仓"},"translate_title":"Shenzhou Cell anti-PD-1 monoclonal antibody combination therapy was approved, Baili Tianheng GNC-038 quaternary antibody injection entered the field of autoimmunity, and Johnson & Johnson gusecchiumab was approved for Crohn's disease indications in China","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688506":0.9,"688520":0.9,"PD":1,"JNJ":1},"content_text":"神州细胞抗PD-1单抗联合疗法获批，一线治疗肝癌2月28日，中国国家药监局（NMPA）官网公示，神州细胞控股子公司神州细胞工程递交的菲诺利单抗注射液（SCT-I10A）与贝伐珠单抗注射液（SCT510）联合疗法的上市许可申请已获得批准。根据神州细胞此前发布的新闻稿，该药本次获批的适应症为：适用于既往未接受过系统治疗的不可切除或转移性肝细胞癌患者。截图来源：NMPA官网据世界卫生组织国际癌症研究机构（IARC）统计，2020年原发性肝癌是全球范围内发病率排名第6位的恶性肿瘤。IARC预测，至2040年，肝癌的新发病例及死亡病例将进一步增加。肝细胞癌（HCC）作为主要的肝癌分型，占原发性肝癌的85%~90%。HCC恶性程度高，现有治疗手段不能满足长久的生存获益，仍存在巨大的未满足的临床需求。菲诺利单抗为神州细胞自主研发的重组人源化抗PD-1 IgG4型单克隆抗体注射液，首个适应症头颈部鳞状细胞癌已经于2025年2月获NMPA批准上市。SCT510为神州细胞自主研发的重组人源化抗VEGF单克隆抗体注射液，是贝伐珠单抗注射液的生物类似药。靶向特异的VEGF抗体药物可以通过阻断游离态VEGF与 VEGF受体（VEGFRs）结合降低肿瘤内部新生血管生成，从而致使肿瘤组织丧失供应生存和增生所需营养环境，提高肿瘤免疫激活环境。SCT510已在中国获批用于转移性结直肠癌，晚期、转移性或复发性非小细胞肺癌，复发性胶质母细胞瘤，肝细胞癌，上皮性卵巢癌、输卵管癌或原发性腹膜癌，宫颈癌的治疗。百利天恒GNC-038 四抗注射液杀入自免领域2月27日，中国药物临床试验登记与信息公示平台显示，百利天恒登记了一项GNC-038四抗注射液在系统性红斑狼疮中的I期临床研究（CTR20250677）。这也是该药首次从肿瘤领域杀入自免领域。截图来源：中国药物临床试验登记与信息公示平台这是一项随机对照 I 期临床研究，旨在评估 GNC-038 四抗在系统性红斑狼疮中的有效性、安全性、耐受性及药代动力学/药效动力学。主要终点包括剂量限制性毒性（DLT）、最大耐受剂量（MTD）、治疗过程中不良事件（TEAE）的发生率和严重程度、药代动力学（PK）参数、II 期临床研究推荐剂量（RP2D）以及试验组和安慰剂组用药后 12 周 SRI-4 的应答率。GNC-038 是百利药业基于 GNC(Guidance&Navigation,Control)平台开发的四特异性结构的“靶向免疫”抗体，具有靶向 CD19、CD3、PD-L1 和 4-1BB 四个抗原的结构域，可激活 T 细胞的第一信号和第二信号，通过抗 CD19、PD-L1 结构域靶向并杀伤肿瘤细胞。该药于 2020 年 6 月首次申请临床，同年 10 月首次启动临床，是全球首个进入临床阶段的四抗。该药此前已经登记了 5 项临床试验，适应症均为血液瘤。此次登记的系统性红斑狼疮临床 I 期是该药布局的首个自免适应症。强生古塞奇尤单抗在华获批克罗恩病适应症2月25日，强生公司宣布其创新药物特诺雅达®（古塞奇尤单抗注射液（静脉输注））和特诺雅®（古塞奇尤单抗注射液）在中国获得批准，用于治疗对传统治疗或生物制剂应答不充分、失应答或不耐受的中度至重度活动性克罗恩病成人患者。这一消息标志着古塞奇尤单抗在克罗恩病适应症上的全球首个批准，为国内克罗恩病患者带来了新的希望。古塞奇尤单抗是一种全人源白介素-23（IL-23）抑制剂，通过选择性中和IL-23的p19亚基，阻断IL-23与其受体的结合，从而抑制炎症反应。IL-23是一种关键的细胞因子，在克罗恩病的发病机制中发挥重要作用，它能够促进Th17细胞的分化和增殖，进而产生多种促炎细胞因子，如IL-17、IL-22等，导致肠道黏膜的炎症和损伤。古塞奇尤单抗通过精准靶向IL-23，从源头上抑制炎症反应，为克罗恩病的治疗提供了新的靶点和思路。编辑：余远泽审校：马飞、张蓝飞、张松7.3%！医械出口增速重回快车道，外贸总额显著回稳李利在中检院调研药品监管科学研究应用工作2025年全国化妆品监督管理工作会议召开www.yyjjb.com.cn洞悉行业趋势长按关注医药经济报《中国处方药》学术公众号聚焦药学学术和循证研究长按关注中国处方药《医药经济报》终端公众号记录药品终端产经大事件长按关注21世纪药店","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2516580463","isCrawlerRequest":true}